{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:33:34Z","timestamp":1794134014304,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.gastro.2025.01.223","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T19:36:21Z","timestamp":1738352181000},"page":"1128-1136.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A Novel, IBS-Specific IgG ELISA-Based Elimination Diet in Irritable Bowel Syndrome: A Randomized, Sham-Controlled Trial"],"prefix":"10.1053","volume":"168","author":[{"given":"Prashant","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Chey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn M.M.","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.01.223_bib1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.01.223_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","article-title":"Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem","volume":"113","author":"Frandemark","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.01.223_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/apt.17132","article-title":"Impact of Rome IV irritable bowel syndrome on work and activities of daily living","volume":"56","author":"Goodoory","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.01.223_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.cgh.2021.07.004","article-title":"Food avoidance and restriction in irritable bowel syndrome: relevance for symptoms, quality of life and nutrient intake","volume":"20","author":"Melchior","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.01.223_bib5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/gutjnl-2021-325214","article-title":"Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis","volume":"71","author":"Black","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.01.223_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.01.223_bib7","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.cgh.2022.02.045","article-title":"Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet, and the gluten-free diet","volume":"20","author":"Rej","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1053\/j.gastro.2025.01.223_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13154","article-title":"Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome","volume":"30","author":"O'Keeffe","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.01.223_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.09.043","article-title":"Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis","volume":"20","author":"Shah","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.01.223_bib10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3390\/nu11061313","article-title":"How patients with IBS use low FODMAP dietary information provided by general practitioners and gastroenterologists: a qualitative study","volume":"11","author":"Trott","year":"2019","journal-title":"Nutrients"},{"key":"10.1053\/j.gastro.2025.01.223_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12986-020-00528-x","article-title":"Food-specific serum IgG and symptom reduction with a personalized, unrestricted-calorie diet of six weeks in irritable bowel syndrome (IBS)","volume":"17","author":"Cappelletti","year":"2020","journal-title":"Nutr Metab (Lond)"},{"key":"10.1053\/j.gastro.2025.01.223_bib12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1526-4610.2012.02296.x","article-title":"IgG-based elimination diet in migraine plus irritable bowel syndrome","volume":"53","author":"Aydinlar","year":"2013","journal-title":"Headache"},{"key":"10.1053\/j.gastro.2025.01.223_bib13","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.3390\/jcm10194317","article-title":"Igg Food Antibody Guided Elimination-Rotation Diet Was More effective than FODMAP diet and control diet in the treatment of women with mixed IBS\u2014results from an open label study","volume":"10","author":"Ostrowska","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.gastro.2025.01.223_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-230X-12-166","article-title":"IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population","volume":"12","author":"Ligaarden","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2025.01.223_bib15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","article-title":"Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial","volume":"53","author":"Atkinson","year":"2004","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.01.223_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/15321810802571903","article-title":"Serum IgG responses to food antigens in the italian population evaluated by highly sensitive and specific ELISA test","volume":"30","author":"Volpi","year":"2009","journal-title":"J Immunoassay Immunochem"},{"key":"10.1053\/j.gastro.2025.01.223_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.01.223_bib18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1023\/A:1024159226274","article-title":"Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy","volume":"48","author":"Gordon","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2025.01.223_bib19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ajg.2009.13","article-title":"Adequate relief in a treatment trial with IBS patients: a prospective assessment","volume":"104","author":"Passos","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.01.223_bib20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.01.223_bib21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.01.223_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.01.223_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.14309\/ajg.0000000000001767","article-title":"The role of food in the treatment of bowel disorders: focus on irritable bowel syndrome and functional constipation","volume":"117","author":"Singh","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.01.223_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/apt.13041","article-title":"Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance","volume":"41","author":"Lomer","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.01.223_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2021.104317","article-title":"Identification of significant potential signaling pathways and differentially expressed proteins in patients with wheat intolerance based on quantitative proteomics","volume":"246","author":"Zhang","year":"2021","journal-title":"J Proteomics"},{"key":"10.1053\/j.gastro.2025.01.223_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-2007-993165","article-title":"IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles","volume":"116","author":"Wilders-Truschnig","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1053\/j.gastro.2025.01.223_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1756284821993586","article-title":"Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review","volume":"14","author":"Hanning","year":"2021","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525003282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525003282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:17:16Z","timestamp":1788949036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525003282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0016508525003282"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.01.223","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel, IBS-Specific IgG ELISA-Based Elimination Diet in Irritable Bowel Syndrome: A Randomized, Sham-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.01.223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}